Clinical Trial Update: Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical study evaluating CAR-T cells targeting CD19 and CD22 for relapsed or refractory B cell non-Hodgkin lymphoma; status not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Snippet

Sponsor: He Huang | Conditions: Relapsed and Refractory, Lymphoid Hematological Malignancies | Phase 1, Phase 2 | Status: UNKNOWN